Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation

Documenti analoghi

• Are we ready for disease modification in myeloproliferative neoplasms?
  di: Claire N. Harrison
  Pubblicazione: (2024)
• A single JAK2 ‐V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non‐conditioned recipient mice
  di: Quentin Kimmerlin, et al.
  Pubblicazione: (2026)
• Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
  di: Romain Stammler, et al.
  Pubblicazione: (2025)
• Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
  di: David A. Sallman, et al.
  Pubblicazione: (2025)
• From hypoxia single‐cell gene signatures to HIF targeting of AML leukemic stem cells
  di: Thomas Mercher, et al.
  Pubblicazione: (2024)